Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
Status:
Completed
Trial end date:
2022-03-11
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to examine the effectiveness of intranasal-administered
Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for
COVID-19. The main questions it aims to answer are:
- To assess the efficacy of nasal spray with Chlorpheniramine (1.0%) for improving
clinical recovery in COVID-19 patients.
- To assess the efficacy, safety, and tolerability of nasal spray with Chlorpheniramine
(1%) as an adjunct to the standard of care in reducing hospitalizations and improving
clinical recovery in adult patients with mild COVID-19.